MW 333.4 Da, Purity >98%. Selective PPARγ agonist (EC50 = 3 μM). Shows antidiabetic and antineoplastic activity. Induces cell cycle arrest and apoptosis. Active in vivo.
Images
Key facts
- CAS number
- 74772-77-3
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 333.4 Da
- Molecular formula
- C18H23NO3S
- PubChem identifier
- 2750
- Nature
- Synthetic
Target data
Alternative names
1,8-cineole 2-exo-monooxygenase, 5 HTT, 5 HTTLPR, 5 hydroxytryptamine (serotonin) transporter, 5 hydroxytryptamine transporter, 5HT transporter, A3AR, A3R, AA3R_HUMAN, ACM3_HUMAN, ACM4_HUMAN, AChR, AD 026, ADA2A_HUMAN, ADORA 3, ADRA2, ADRA2A, ADRA2R, ADRA2RL1, ADRAR, ADRARL1, AI838772, ARA3, AW493413, Adenosine A3 receptor, Adenosine receptor A3, Adrenergic alpha 2A receptor, Albendazole monooxygenase, Albendazole sulfoxidase, Alpha 2 adrenergic receptor subtype C2, Alpha 2AAR subtype C10, Alpha 2B adrenoceptor, Alpha 2B adrenoreceptor, Alpha-2 adrenergic receptor subtype C10, Alpha-2A adrenergic receptor, Alpha-2A adrenoceptor, Alpha-2A adrenoreceptor, Alpha-2AAR, Amine oxidase (flavin containing), Amine oxidase (flavin containing) A, Amine oxidase (flavin containing) B, Antigen NY-CO-13, BAR, BCC7, BXR, Bile acid receptor, CHRM 3, CP33, CP34, CP3A4_HUMAN, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, Cellular tumor antigen p53, Cholinergic receptor muscarinic 4, Chrm 4, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450-PCN1, D(1A) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor, D-OR-1, D1A dopamine receptor, DADR, DRD 1A, DRD1_HUMAN, Delta type opioid receptor DOR 1, Delta-type opioid receptor, Dopamine D1 receptor, Dopamine D2 receptor, Dopamine D3 receptor, EGBRS, FLJ11090, FLJ92943, Farnesoid X-activated receptor, Farnesol receptor HRR-1, GCN5 general control of amino acid synthesis 5 like 2, GPCR 2, Glucocorticoid inducible P450, HLP, HM 3, HM 4, HRR 1, LFS1, M3 muscarinic receptor, M4, MAO, MAO-A, MAO-B, MGC104252, MGC112732, MGC126680, Monoamine oxidase, Monoamine oxidase A, Monoamine oxidase B, Monoamine oxidase type A, Monoamine oxidase type B, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4, Mutant tumor protein 53, NF 25, NK-2 receptor, NK2R_HUMAN, NKNAR, NR1B1, NR1C3, NR1I2_HUMAN, Na+/Cl- dependent serotonin transporter, Nbor, Neurokinin 2 receptor, Neurokinin A receptor, Neurotransmitter transporter, Nifedipine oxidase, Norepinephrine transporter, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group I member 2, Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, OCD1, ONR 1, OPRD 1, OPRD_HUMAN, OTTHUMP00000058849, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Opioid receptor delta 1, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, P53_HUMAN, PAR, PAR q, PPAR-gamma, PPARG2, PPARG_HUMAN, PRR, Peroxisome proliferator activated receptor gamma 2, Peroxisome proliferator-activated receptor gamma, Phosphoprotein p53, Pregnane X receptor, Quinine 3-monooxygenase, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, RIP 14, RP11 552M11.7, RP24-311F12.2, RXR-interacting protein 14, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Retinoid X receptor-interacting protein 14, SC6A2_HUMAN, SC6A4_HUMAN, SCAN1, SERT, SERT1, SKR, SLC6A5, SXR, Serotonin transporter 1, Seven transmembrane helix receptor, Slc6a2, Slc6a4, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Solute carrier family 6 (neurotransmitter transporter norepinephrine) member 5, Solute carrier family 6 (neurotransmitter transporter) member 4, Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, Solute carrier family 6 member 4, Solute carrier family 6 member 5, Steroid and xenobiotic receptor, Substance-K receptor, TAC 2R, TAC R2, TACR 2, TACR2, TGPCR1, TRP53, TYDP, TYDP1_HUMAN, Tachykinin receptor 2, Tachykinin receptor 2 (substance K receptor; neurokinin 2 receptor), Taurochenodeoxycholate 6-alpha-hydroxylase, Tp53, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, alpha 2BAR, alpha-2-adrenergic receptor, platelet type, bA552M11.5, cholinergic receptor muscarinic 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, dopamine receptor D1, hSERT, m3 muscarinic acetylcholine receptor, mDOR, muscarinic 3, muscarinic cholinergic m3 receptor, muscarinic m3 receptor, p53 tumor suppressor, pregnane X nuclear receptor variant 2, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, tumor antigen p55
Recommended products
MW 333.4 Da, Purity >98%. Selective PPARγ agonist (EC50 = 3 μM). Shows antidiabetic and antineoplastic activity. Induces cell cycle arrest and apoptosis. Active in vivo.
Key facts
- CAS number
- 74772-77-3
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 333.4 Da
- Molecular formula
- C18H23NO3S
- PubChem identifier
- 2750
- Nature
- Synthetic
- Solubility
Soluble in DMSO to 100 mM.
Soluble in 1eq. NaOH to 100 mM.
- Biochemical name
- Ciglitazone
- Biological description
Selective PPARγ agonist (EC50 = 3 μM). Shows antidiabetic and antineoplastic activity. Induces cell cycle arrest and apoptosis. Active in vivo.
- Canonical SMILES
- CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
- InChI
- InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)
- InChIKey
- YZFWTZACSRHJQD-UHFFFAOYSA-N
- IUPAC name
- 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- Ambient
- Appropriate long-term storage conditions
- Ambient
- Storage information
- The product can be stored for up to 12 months
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Chemical Structure - Ciglitazone, PPARgamma agonist (ab141139)
2D chemical structure image of ab141139, Ciglitazone, PPARgamma agonist
Functional Studies - Ciglitazone, PPARgamma agonist (ab141139)
ab19481 staining PPARγ in U-87 MG cells treated with ciglitazone (ab141139), by ICC/IF. Increase of PPARγ cytoplasmic expression correlates with increased concentration of ciglitazone, as described in literature.
The cells were incubated at 37°C for 24 hours in media containing different concentrations of ab141139 (ciglitazone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab19481 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com